Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1948 1
1951 2
1959 1
1960 1
1961 1
1998 4
1999 7
2000 4
2001 4
2002 12
2003 26
2004 31
2005 32
2006 39
2007 44
2008 45
2009 53
2010 55
2011 54
2012 69
2013 77
2014 95
2015 87
2016 113
2017 92
2018 101
2019 97
2020 86
2021 90
2022 84
2023 82
2024 80
2025 74
2026 55

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,481 results

Results by year

Filters applied: . Clear all
Page 1
Aprepitant and Fosaprepitant for Preventing Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy-A Real-World Study.
Ünlü B, Demir H, Davarcı SE, Culha Y, Özaşkın D, Özkan FE, Yıldız S, Yıldız C, Baykara M. Ünlü B, et al. Curr Oncol. 2026 Jun 24;33(7):381. doi: 10.3390/curroncol33070381. Curr Oncol. 2026. PMID: 42505183 Free PMC article.
Neurokinin-1 receptor antagonists, including oral aprepitant and intravenous fosaprepitant, constitute essential components of antiemetic regimens for highly emetogenic chemotherapy. ...These findings indicate that no statistically significant differences in antiemetic eff …
Neurokinin-1 receptor antagonists, including oral aprepitant and intravenous fosaprepitant, constitute essential components of antiem …
Neurokinin-1 Receptor Inhibition and Cough.
Turner RD, Birring SS. Turner RD, et al. Am J Respir Crit Care Med. 2021 Mar 15;203(6):672-674. doi: 10.1164/rccm.202010-3783ED. Am J Respir Crit Care Med. 2021. PMID: 33108214 Free PMC article. No abstract available.
Aprepitant use during chemotherapy and association with survival in women with early breast cancer.
Botteri E, Hjorth S, Conforti F, Bagnardi V, Andreassen BK, Støer NC, Bhargava S, Ursin G, Gandini S, Sloan EK, Chang A. Botteri E, et al. J Natl Cancer Inst. 2025 Nov 1;117(11):2249-2258. doi: 10.1093/jnci/djaf178. J Natl Cancer Inst. 2025. PMID: 40658620 Free PMC article.
BACKGROUND: Preclinical studies have shown that aprepitant, an antiemetic used to prevent chemotherapy-induced nausea and vomiting, slows mammary tumor growth and progression. ...RESULTS: During chemotherapy, 7047 (51%) women were supplied with aprepitant. Overall, …
BACKGROUND: Preclinical studies have shown that aprepitant, an antiemetic used to prevent chemotherapy-induced nausea and vomiting, s …
Pharmacokinetic evaluation of fosaprepitant dimeglumine.
Colon-Gonzalez F, Kraft WK. Colon-Gonzalez F, et al. Expert Opin Drug Metab Toxicol. 2010 Oct;6(10):1277-86. doi: 10.1517/17425255.2010.513970. Expert Opin Drug Metab Toxicol. 2010. PMID: 20795794 Free PMC article. Review.
Fosaprepitant, a prodrug of aprepitant, was introduced to the market in 2008 as an intravenous bioequivalent to aprepitant. ...TAKE HOME MESSAGE: Fosaprepitant is an intravenous prodrug of aprepitant that offers a new alternative to patients with CINV. Curren …
Fosaprepitant, a prodrug of aprepitant, was introduced to the market in 2008 as an intravenous bioequivalent to aprepitant. .. …
Highly effective use of aprepitant in an adolescent girl with severe cyclic vomiting syndrome.
Nivatsi M, Aslanidou I, Mantadakis E. Nivatsi M, et al. BMJ Case Rep. 2021 Mar 4;14(3):e241132. doi: 10.1136/bcr-2020-241132. BMJ Case Rep. 2021. PMID: 33664041 Free PMC article.
She had failed oral ondansetron therapy. Oral aprepitant (125 mg in the first, and 85 mg on the second and third days), a neurokinin 1 receptor antagonist that has been approved for preventing chemotherapy-induced vomiting or postoperative emesis, was tried in our patient …
She had failed oral ondansetron therapy. Oral aprepitant (125 mg in the first, and 85 mg on the second and third days), a neurokinin …
New antiemetic drugs.
Roila F, Fatigoni S. Roila F, et al. Ann Oncol. 2006 Mar;17 Suppl 2:ii96-100. doi: 10.1093/annonc/mdj936. Ann Oncol. 2006. PMID: 16608997 Free article. Review.
METHODS: A critical review of the results of published studies of aprepitant, a new NK1 receptor antagonist, and of palonosetron, a 5-HT3 receptor antagonist with a longer half-life. ...For cisplatin nausea, aprepitant combined with dexamethasone significantly incre …
METHODS: A critical review of the results of published studies of aprepitant, a new NK1 receptor antagonist, and of palonosetron, a 5 …
Safety of neurokinin-1 receptor antagonists.
Muñoz M, Coveñas R. Muñoz M, et al. Expert Opin Drug Saf. 2013 Sep;12(5):673-85. doi: 10.1517/14740338.2013.804059. Epub 2013 May 25. Expert Opin Drug Saf. 2013. PMID: 23706125 Review.
However, the only NK-1 receptor antagonist used in clinical practice is the drug aprepitant and its intravenously administered prodrug, fosaprepitant. In general, NK-1 receptor antagonists are safe and well tolerated. ...EXPERT OPINION: Most clinical trials have focused on …
However, the only NK-1 receptor antagonist used in clinical practice is the drug aprepitant and its intravenously administered prodru …
Anti-Metastatic Effects of Aprepitant on Glioblastoma Cells: Targeting the Substance P/Neurokinin-1 Pathway.
Engür-Öztürk S, Kaya-Tilki E, Dikmen M. Engür-Öztürk S, et al. Cancer Med. 2025 Aug;14(15):e71148. doi: 10.1002/cam4.71148. Cancer Med. 2025. PMID: 40808496 Free PMC article.
METHODS: This study investigates the anti-metastatic effects of aprepitant on U87-MG glioblastoma cells. Cell viability, migration, and invasion were evaluated using WST-1, real-time cell analysis, and Oris migration assays. Gene and protein expression levels were assessed …
METHODS: This study investigates the anti-metastatic effects of aprepitant on U87-MG glioblastoma cells. Cell viability, migration, a …
A New Adjuvant Treatment for Glioblastoma Using Aprepitant, Vortioxetine, Roflumilast and Olanzapine: The AVRO Regimen.
Kast RE, Marques Vieira B, Barros da Silva E Jr. Kast RE, et al. Int J Mol Sci. 2025 Jun 26;26(13):6158. doi: 10.3390/ijms26136158. Int J Mol Sci. 2025. PMID: 40649933 Free PMC article. Review.
AVRO is a repurposed drug regimen consisting of the antinausea drug aprepitant, the antidepressant vortioxetine, the emphysema treatment drug roflumilast, and the antipsychotic drug olanzapine. ...The goal of adding AVRO is to further retard GB growth, improving survival. …
AVRO is a repurposed drug regimen consisting of the antinausea drug aprepitant, the antidepressant vortioxetine, the emphysema treatm …
Aprepitant and fosaprepitant drug interactions: a systematic review.
Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Patel P, et al. Br J Clin Pharmacol. 2017 Oct;83(10):2148-2162. doi: 10.1111/bcp.13322. Epub 2017 Jun 10. Br J Clin Pharmacol. 2017. PMID: 28470980 Free PMC article.
AIMS: Aprepitant and fosaprepitant, commonly used for the prevention of chemotherapy-induced nausea and vomiting, alter cytochrome P450 activity. This systematic review evaluates clinically significant pharmacokinetic drug interactions with aprepitant and fosaprepit …
AIMS: Aprepitant and fosaprepitant, commonly used for the prevention of chemotherapy-induced nausea and vomiting, alter cytochrome P4 …
1,481 results